Company intelligence / Profile preview
SIFI SpA
Aci S. Antonio, Catania, Sicilia (Sicily), Italysifigroup.com ↗
- Ownership
- Public · SIFI
- Employees
- ~618
- Development stage
- Commercial
01
Overview
SIFI has multiple approved products including Dexamethasone/Netilmicin Sulfate for ocular inflammation and Polihexanide for Acanthamoeba Keratitis. The company also has products in NDA/BLA stage (PH011 for Glaucoma) and Phase 2 (PH006 for Hypersensitivity and PH007 for Dry Eye Syndromes)[8].
- Therapeutic areas
- OphthalmologyImmunologyInfectious Diseases
- Modalities
- Small moleculesPolymersChemical drugs
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →03
Partnerships
Zydus CadilaAffaMed Therapeutics
04
Financials
- Market cap
- $33.7M
- Total revenue
- $15.7M
- Enterprise value
- $-226.1M
Beyond the preview
Go deeper on SIFI SpA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SIFI SpA.